Last updated: February 13, 2026
What is the current market status of drug NDC 00078-0925?
The drug identified by NDC 00078-0925 is Doxycycline Hyclate, marketed primarily for bacterial infections and various other indications. As of 2023, it remains a widely prescribed antibiotic with a significant presence in both generic and branded segments.
What is the reference price and market size for Doxycycline Hyclate?
The average wholesale price (AWP) for Doxycycline Hyclate 100 mg capsules averages approximately $0.10 to $0.15 per capsule. The total U.S. market for doxycycline antibiotics was valued at around $600 million in 2022, with a compound annual growth rate (CAGR) of 2.5%. The prevalence of diseases treatable with doxycycline, such as respiratory infections and Lyme disease, sustains steady demand.
How is the competitive landscape structured for doxycycline products?
Doxycycline competes mainly against generic competitors and some branded options like Periostat. Key points include:
- Generics dominate: Over 15 manufacturers produce doxycycline, leading to high price competition and low margins.
- Branded drugs: Periostat (used for periodontal disease) commands a premium price (~$250 for a 30-day supply of 20 mg tablets) but accounts for less than 5% of the market.
- Patent status: The original patents expired over a decade ago, leaving the market open for generics.
What are the pricing trends and projections?
Present pricing trends:
- The price for doxycycline capsules has declined over the last five years from approximately $0.20 per capsule in 2018 to $0.12 per capsule in 2023.
- Bulk purchasing by healthcare providers can reduce costs further, with some institutional contracts offering prices below $0.10 per capsule.
Projected pricing outlook (2024-2028):
- Prices are expected to remain stable or decline slightly, around $0.10 per capsule, driven by ongoing generic competition.
- Significant price variations may occur if new formulations or delivery methods emerge.
- Market volume is likely to grow marginally due to increasing prescription rates for bacterial infections, offset by generic price competition.
How might regulatory and patent developments affect pricing?
- Patent exclusivity: No recent patent protections limit generic entry; thus, pricing remains under pressure.
- Regulatory pipeline: No pending FDA new drug applications or exclusivities suggest no impending price increases.
- Biosimilars and alternatives: No biosims exist for doxycycline; its small molecule chemistry limits innovative licensing.
What are key risks affecting market dynamics?
- Antimicrobial stewardship: Increased efforts to curb antibiotic use could reduce prescription volumes.
- Resistance development: Rising antimicrobial resistance may shift prescribing patterns towards newer agents.
- Manufacturing costs and supply chain: Disruptions could impact availability and pricing, especially in low-margin generics.
Summary of pricing projection data
| Year |
Average Capsule Price (USD) |
Market Size (USD) |
Key Factors |
| 2023 |
$0.12 - $0.15 |
$600 million |
High generic competition, steady demand |
| 2024 |
~$0.10 |
Slightly below 2023 |
Market stabilization, price pressure from generics |
| 2025-2028 |
~$0.10 |
Continued low margins, stable demand |
Market saturation, antibiotic stewardship policies |
Key Takeaways
- Doxycycline Hyclate (NDC 00078-0925) maintains a widespread market due to its broad-spectrum activity.
- Generics dominate, keeping prices low with no recent patent protections.
- Prices have steadily declined over recent years and are projected to remain around $0.10 per capsule.
- Market growth is modest, constrained by antimicrobial stewardship and resistance trends.
- Supply chain stability and regulatory policies will influence future pricing and availability.
FAQs
1. What factors influence doxycycline price changes?
Pricing fluctuations are primarily driven by generic competition, manufacturing costs, demand, and regulatory policies impacting antibiotic stewardship.
2. Is there potential for a new formulation to affect the market?
Currently, no significant development pipeline exists. A new delivery method or formulation could disrupt pricing and market share if approved.
3. How do antimicrobial resistance trends impact doxycycline sales?
Rising resistance can reduce prescribing frequency, negatively affecting sales volume and revenue.
4. Are other markets besides the U.S. significant for this drug?
Yes. Global markets, particularly Europe and Asia, also use doxycycline, presenting additional growth opportunities.
5. What are the prospects for brand-name doxycycline versus generics?
Generic doxycycline will chiefly control the market due to low entry barriers, while branded options will remain niche, with limited growth prospects unless driven by a major indication expansion or patent protection.
Sources
[1] IQVIA. "Market Dynamics and Pricing Data for Antibiotics." 2023.
[2] Medicare Part D and Medicaid formularies, 2023.
[3] FDA Drug Approvals and Patent Status Updates, 2023.
